U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511400) titled 'The Role of NaV1.8 in Human Pain Models' on March 28.
Brief Summary: This study aims to understand how NaV1.8, a specific type of sodium channel found in peripheral nerves, contributes to different types of pain in humans. To address this, suzetrigine, a highly selective blocker of the NaV1.8 channel, is used. While current pain medications often have side effects that limit their use, NaV1.8 is a promising target for new, non-opioid pain treatments because it is primarily located in the nerves that send pain signals to the brain.
This study is a randomised, placebo-controlled double-blind crossover microdosing trial. This means th...